When Aventis S.A. restructured its internal gene therapy operations and attenuated its role in its gene therapy partnership with Introgen Therapeutics Inc. in April, the pharma company said the moves were designed to retain its focus on protein therapeutics and vaccines. Last week, the pharma company partnered with BioVex Ltd. to evaluate gene therapy vectors. However, instead of delving back into the gene therapy arena, the deal is more geared to functional genomics research and vaccine development.

Under the first